📊 CVKD Key Takeaways
Is Cadrenal Therapeutics, Inc. (CVKD) a Good Investment?
Cadrenal Therapeutics is a pre-revenue clinical-stage pharmaceutical company with severe negative fundamentals and rapidly depleting cash resources. The company is burning approximately $10M annually with no revenue generation and only ~13 months of cash runway remaining, making near-term capital raise or partnership critical for survival.
Cadrenal Therapeutics shows a highly speculative fundamental profile: it has no reported revenue, produces recurring operating and free cash flow losses of about $10 million, and generates deeply negative returns on equity and assets. While the balance sheet is not levered and liquidity is currently above 3x, the cash balance of $3.86 million appears thin relative to its burn rate, making financing risk and potential dilution the central fundamental concern.
Why Buy Cadrenal Therapeutics, Inc. Stock? CVKD Key Strengths
- Adequate short-term liquidity with $3.9M cash representing 95% of total assets
- Low debt burden with zero long-term debt and minimal leverage
- Maintains current ratio of 3.02x, indicating ability to cover short-term obligations
- No meaningful long-term debt, which limits balance-sheet leverage risk
- Current and quick ratios of 3.02x indicate near-term liabilities are presently covered
- Cash represents most of total assets, giving the company some short-term operating flexibility
CVKD Stock Risks: Cadrenal Therapeutics, Inc. Investment Risks
- Zero revenue with no clear commercialization timeline for pipeline assets
- Negative operating cash flow of -$10.0M annually indicates unsustainable burn rate
- Severely negative ROE (-372.9%) and ROA (-249.5%) reflect value destruction
- Cash runway of approximately 13 months at current burn rate creates existential liquidity risk
- EPS of -$5.23 on minimal equity base demonstrates pre-commercial stage weakness
- Single Form 4 insider filing in last 90 days suggests minimal insider investment confidence
- No revenue base or gross profit, so the business is not yet commercially self-supporting
- Operating cash flow and free cash flow are deeply negative, indicating a weak standalone funding profile
- Very small equity base and limited cash relative to annual losses raise a high likelihood of future capital raises
Key Metrics to Watch
- Operating cash flow trend and monthly burn rate trajectory
- Time-to-cash-depletion and capital raise announcements
- Clinical trial progress, regulatory approvals, and partnership developments
- Cash balance changes and dilution from future financing activities
- Any revenue generation milestones or commercialization progress
- Cash and equivalents relative to quarterly operating cash burn
- Quarterly operating loss trend and any emergence of collaboration or product revenue
Cadrenal Therapeutics, Inc. (CVKD) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.02x current ratio provides a solid financial cushion.
CVKD Profit Margin, ROE & Profitability Analysis
CVKD vs Healthcare Sector: How Cadrenal Therapeutics, Inc. Compares
How Cadrenal Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Cadrenal Therapeutics, Inc. Stock Overvalued? CVKD Valuation Analysis 2026
Based on fundamental analysis, Cadrenal Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Cadrenal Therapeutics, Inc. Balance Sheet: CVKD Debt, Cash & Liquidity
CVKD Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Cadrenal Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-8.73 indicates the company is currently unprofitable.
CVKD Revenue Growth, EPS Growth & YoY Performance
Cadrenal Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
CVKD SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Cadrenal Therapeutics, Inc. (CIK: 0001937993)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CVKD
What is the AI rating for CVKD?
Cadrenal Therapeutics, Inc. (CVKD) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 92% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CVKD's key strengths?
Claude: Adequate short-term liquidity with $3.9M cash representing 95% of total assets. Low debt burden with zero long-term debt and minimal leverage. ChatGPT: No meaningful long-term debt, which limits balance-sheet leverage risk. Current and quick ratios of 3.02x indicate near-term liabilities are presently covered.
What are the risks of investing in CVKD?
Claude: Zero revenue with no clear commercialization timeline for pipeline assets. Negative operating cash flow of -$10.0M annually indicates unsustainable burn rate. ChatGPT: No revenue base or gross profit, so the business is not yet commercially self-supporting. Operating cash flow and free cash flow are deeply negative, indicating a weak standalone funding profile.
What is CVKD's revenue and growth?
Cadrenal Therapeutics, Inc. reported revenue of N/A.
Does CVKD pay dividends?
Cadrenal Therapeutics, Inc. does not currently pay dividends.
Where can I find CVKD SEC filings?
Official SEC filings for Cadrenal Therapeutics, Inc. (CIK: 0001937993) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CVKD's EPS?
Cadrenal Therapeutics, Inc. has a diluted EPS of $-5.23.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CVKD a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Cadrenal Therapeutics, Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CVKD stock overvalued or undervalued?
Valuation metrics for CVKD: ROE of -372.9% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CVKD stock in 2026?
Our dual AI analysis gives Cadrenal Therapeutics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CVKD's free cash flow?
Cadrenal Therapeutics, Inc.'s operating cash flow is $-10.0M, with capital expenditures of $5.1K.
How does CVKD compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -372.9% (avg: 15%), current ratio 3.02 (avg: 2).